In clinical practice, some centers treat high-risk ACC patients (Ki-67 > 10%) with mitotane alone for 2 to 3 years, and other centers administer a combination of mitotane with platinum-based chemotherapy. The gene discussed is MKI67; the disease is adrenal cortex carcinoma.